Shares of BioCryst Pharmaceuticals (NASDAQ: BCRX), a clinical-stage biotech focused on treating rare diseases, popped after the company announced the appointment of a new board member. The stock jumped 15.7% higher in midday trading and ended Monday's session with a 12.9% gain.
Investor-relations departments have to issue a release whenever members of a board of directors come and go, but they rarely move biotech stocks this far. BioCryst's stock soared today because its new board member is Dr. Helen Thackray, the chief medical officer (CMO) of GlycoMimetics (NASDAQ: GLYC).
Image source: Getty Images.